Kodiak Sciences Dirección
Dirección controles de criterios 3/4
El CEO de Kodiak Sciences' es Victor Perlroth , nombrado en Jun 2009, tiene una permanencia de 15.08 años. compensación anual total es $2.73M, compuesta por 26.4% salario y 73.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.03% de las acciones de la empresa, por valor de $6.19M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 6.1 años, respectivamente.
Información clave
Victor Perlroth
Chief Executive Officer (CEO)
US$2.7m
Compensación total
| Porcentaje del salario del CEO | 26.4% |
| Permanencia del CEO | 15.1yrs |
| Participación del CEO | 5.0% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$233m |
| Dec 31 2023 | US$3m | US$721k | -US$260m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$309m |
| Dec 31 2022 | US$3m | US$691k | -US$334m |
| Sep 30 2022 | n/a | n/a | -US$357m |
| Jun 30 2022 | n/a | n/a | -US$347m |
| Mar 31 2022 | n/a | n/a | -US$312m |
| Dec 31 2021 | US$113m | US$655k | -US$267m |
| Sep 30 2021 | n/a | n/a | -US$220m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$159m |
| Dec 31 2020 | US$9m | US$591k | -US$133m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$64m |
| Dec 31 2019 | US$18m | US$526k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$6m | US$428k | -US$41m |
| Sep 30 2018 | n/a | n/a | -US$38m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$824k | US$388k | -US$28m |
Compensación vs. Mercado: La compensación total de Victor($USD2.73M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD678.50K).
Compensación vs. Ingresos: La compensación de Victor ha sido consistente con los resultados de la empresa en el último año.
CEO
Victor Perlroth (51 yo)
15.1yrs
Permanencia
US$2,725,068
Compensación
Dr. Victor Perlroth, M.D co-founded Kodiak Sciences Inc. in 2009 and serves as its co-founder, Chairman, President and Chief Executive Officer. Dr. Perlroth serves as Chief Executive officer since June 200...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 15.1yrs | US$2.73m | 5.03% $ 5.8m | |
| Executive VP | 10.1yrs | US$1.68m | 0.35% $ 400.8k | |
| Senior Vice President of Discovery Medicine | 6.8yrs | US$321.91k | sin datos | |
| Senior Vice President of Chemical Development & Manufacturing | 1.5yrs | sin datos | sin datos | |
| Chief Quality Officer | 4.5yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.5yrs | sin datos | sin datos | |
| VP & Corporate Controller | 1.5yrs | sin datos | sin datos |
4.5yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KOD se considera experimentado (4.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 15.1yrs | US$2.73m | 5.03% $ 5.8m | |
| Lead Independent Director | 6.1yrs | US$248.40k | 0.019% $ 22.0k | |
| Independent Director | 8.8yrs | US$161.90k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$211.90k | 0.0019% $ 2.2k | |
| Independent Director | 6.1yrs | US$216.90k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$239.40k | 0.050% $ 57.1k | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos |
6.1yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de KOD se considera experimentada (6 años de antigüedad promedio).